Entrada Therapeutics, Inc.
TRDANasdaq
$6.89
↑ +0.3%Jul 17 close · end-of-day
Price
1Y↑ +8.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$288.3M
Enterprise Value
$211.8M
P/E
—
P/S
50.2
P/B
1.1
EV/EBITDA
—
PEG
—
FCF Yield
-45.7%
Dividend Yield
—
Revenue (TTM)
$5.7M
Net Income (TTM)
-$166.1M
Free Cash Flow (TTM)
-$131.8M
Gross Margin
—
Operating Margin
-3109.3%
Net Margin
-2895.1%
ROE
-61.3%
ROIC
-72.5%
Debt / Equity
—
Net Cash
$76.4M
Return 1Y
+8.0%
Company profile
Entrada Therapeutics, Inc. develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for Duchenne muscular dystrophy and myotonic dstrophy type 1.
- CEO
- Dipal Doshi
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 110
- Headquarters
- Massachusetts
- Website
- entradatx.com
Earnings
TRDA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$875,000.00↓ -95.7%
Diluted EPS-$0.95↑ +126.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $129.0M | $210.8M | $25.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$26.7M | -$51.1M | -$97.2M | -$3.2M | $47.0M | -$157.9M |
| Net income | -$26.5M | -$51.2M | -$94.6M | -$6.7M | $65.6M | -$143.8M |
| Diluted EPS | -$24.00 | -$8.16 | -$3.02 | -$0.20 | $1.68 | -$3.47 |
| Operating cash flow | -$25.6M | -$50.9M | -$93.8M | $139.8M | -$41.6M | -$128.5M |
| Free cash flow | -$27.9M | -$55.4M | -$96.7M | $134.2M | -$44.7M | -$129.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | -2.5% | 22.3% | -621.1% |
| Net margin | — | — | — | -5.2% | 31.1% | -565.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $94.7M | $19.6M | $37.4M | $20.6M | $1.9M | $1.6M | $1.3M | $875,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $53.4M | -$21.7M | -$5.9M | -$21.8M | -$46.8M | -$47.1M | -$42.2M | -$42.3M |
| Net income | $55.0M | -$14.0M | $1.1M | -$17.3M | -$43.1M | -$44.1M | -$39.2M | -$39.7M |
| Diluted EPS | $1.55 | -$0.35 | -$0.20 | -$0.42 | -$1.04 | -$1.06 | -$0.95 | -$0.95 |
| Operating cash flow | $39.8M | -$24.3M | -$31.6M | -$38.5M | -$29.5M | -$28.3M | -$32.2M | -$41.7M |
| Free cash flow | $38.8M | -$24.9M | -$32.2M | -$39.7M | -$29.8M | -$28.5M | -$32.4M | -$41.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 56.4% | -110.7% | -15.7% | -106.0% | -2402.5% | -2915.2% | -3249.3% | -4834.6% |
| Net margin | 58.1% | -71.7% | 3.0% | -84.4% | -2210.4% | -2734.4% | -3014.9% | -4539.1% |
Company news
May 7, 2026
- 74d agoSarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?finance.yahoo.com
- 74d agoSector Update: Health Care Stocks Softer Late Afternoonfinance.yahoo.com
- 74d agoEntrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimatesfinance.yahoo.com
- 74d agoEntrada shares dive as Duchenne results disappointbiopharmadive.com
- 74d agoEntrada Therapeutics Reports First Quarter 2026 Financial Resultsfinance.yahoo.com
- 74d agoEntrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Studyfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.